Ever Fortune. AI Co

Ever Fortune. AI Co Net Debt / EBITDA

The Net Debt to EBITDA of Ever Fortune. AI Co (6841.TWO) as of Oct 21, 2026 is 0.21. In the previous year, Net Debt to EBITDA was 31.25 — a change of -99.33% (lower).

Net Debt / EBITDA

0.21

YoY

-99.33%

Last updated:

Net Debt to EBITDA of Ever Fortune. AI Co is 2024 0.21 . Net Debt to EBITDA of Ever Fortune. AI Co was 2023 31.25 . It decreases by -99.33% lower compared to the previous year.

The Ever Fortune. AI Co Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2018
42.79 TWD
Jan 1, 2019
-0.12 TWD
Jan 1, 2020
22.43 TWD
Jan 1, 2021
18.77 TWD
Jan 1, 2022
-8.78 TWD
Jan 1, 2023
31.25 TWD
Jan 1, 2024
0.21 TWD
The Ever Fortune. AI Co Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
0.21-99.33%
31.25-455.83%
-8.78-146.80%
18.77-16.33%
22.43-19,424.44%
-0.12-100.27%
42.79—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ever Fortune. AI Co Stock analysis

What does Ever Fortune. AI Co do? Ever Fortune.AI Co., Ltd. generates revenue through the sale of medical AI software products and customized technology solutions. The company offers medical big data platforms, cloud biomedical services, and AI-driven tools such as the radiographic bone age-assisted interpretation system, ultrasound breast tumor auxiliary classification system, and CT liver cancer metastasis risk management system. These products target healthcare providers, hospitals, and medical institutions seeking advanced diagnostic and analytical capabilities. The firm's focus on specialized medical AI applications ensures consistent demand from clients requiring precision in radiology, oncology, and cardiology. The company's revenue streams include the provision of medical AI data analysis services and tailored AI technology solutions for healthcare facilities. Products like the liver fibrosis evaluation system and irregular cardiac fibrillation interpretation system are designed to address specific clinical needs, enhancing diagnostic accuracy. Healthcare organizations, particularly those in radiology and cardiology departments, purchase these tools to improve patient outcomes and operational efficiency. Ever Fortune.AI's business model centers on delivering high-value AI solutions for medical diagnostics, with a portfolio that includes both standardized products and custom-developed systems. The firm's offerings cater to hospitals and medical institutions looking to integrate AI into their diagnostic workflows. By focusing on niche medical applications, the company establishes itself as a specialized provider in the healthcare technology sector. Ever Fortune. AI Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ever Fortune. AI Co stock

Net Debt to EBITDA of Ever Fortune. AI Co is 0.21 in 2024.

Net Debt to EBITDA of Ever Fortune. AI Co changed from 31.25 to 0.21, representing a -99.33% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Ever Fortune. AI Co since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Ever Fortune. AI Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Ever Fortune. AI Co

All Key Metrics — Ever Fortune. AI Co